跳至主要内容
临床试验/IRCT20191015045113N1
IRCT20191015045113N1已完成3 期

Effect of zinc supplementation on serum zinc status, lipid profile, liver enzymes (ALT, AST), insulin resistance, inflammatory markers and oxidative stress in non-alcoholic fatty liver patients

Shiraz University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 70 years(—)
性别
All

入选标准

  • Attention to fatty liver confirmed by ultrasound
  • - Ages between 18 and 70 years
  • -Not consuming alcoholic beverages
  • - Lack of other liver diseases such as viral hepatitis, liver cirrhosis, Wilson's disease ...
  • - Lack of parenteral nutrition
  • -No diseases that affect the bile and bile ducts
  • - No severe weight loss 6 months ago
  • -Not taking medications that cause fatty liver (methotrexate, tamoxifen, valproate, etc.)
  • -No pregnancy and breastfeeding
  • - Lack of serum ALT levels more than 10 times the limit
  • - No chemotherapy during the past year
  • -Not taking any supplements containing zinc

排除标准

  • People who have done chemotherapy over the past year
  • People with any biliary disease
  • People taking any supplements and drugs containing zinc
  • People who have had severe weight loss in the past 6 month
  • People taking any form of fatty liver medication

研究者

相似试验